Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPOND: Iluvien in chronic diabetic macular edema insufficiently responsive to prior therapies
2014-003491-23Phase 4Completed
- Sponsor
- AIBILI
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluocinolone in diabetic macular edema (DME), sponsored by AIBILI. Primary endpoint: Change in BCVA from baseline to Month 12. Started Oct 2014; status: completed.
02
Drugs
fluocinolone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2014-003491-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003491-23.